X4 Pharmaceuticals GAAP EPS of -$0.18 misses by $0.01, revenue of $0.56M misses by $1.13M

X4 Pharmaceuticals press release ( NASDAQ: XFOR ): Q3 GAAP EPS of -$0.18 misses by $0.01 .

Revenue of $0.56M misses by $1.13M .



X4 had $135.8 million in cash, cash equivalents, restricted cash, and short-term marketable securities as of September 30, 2024. The Company believes it has sufficient funds to support operations into late 2025 and notes that this projected runway does not include potential future XOLREMDI revenue.

More on X4 Pharmaceuticals Seeking Alpha’s Quant Rating on X4 Pharmaceuticals Historical earnings data for X4 Pharmaceuticals Financial information for X4 Pharmaceuticals.